LOG IN
SIGN UP
MARKET
FUSN
FUSN
Fusion Pharmaceuticals Inc.
NASDAQ
4.320
+0.090
+2.13%
Closed 17:21 05/30 EDT
OPEN
4.250
PREV CLOSE
4.230
HIGH
4.420
LOW
4.220
VOLUME
31.82K
TURNOVER
--
52 WEEK HIGH
5.22
52 WEEK LOW
1.980
MARKET CAP
275.81M
P/E (TTM)
-2.1697
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Genmab (GMAB) and Fusion Pharmaceuticals (FUSN)
TipRanks · 05/23 15:50
Fusion Pharmaceuticals Inc.: [Amend]General statement of acquisition of beneficial ownership
Press release · 05/16 16:29
SVB Securities Sticks to Their Buy Rating for Fusion Pharmaceuticals (FUSN)
TipRanks · 05/15 10:06
JonesTrading Sticks to Its Buy Rating for Fusion Pharmaceuticals (FUSN)
TipRanks · 05/12 11:45
Fusion Pharmaceuticals GAAP EPS of -$0.45 misses by $0.23
Seeking Alpha · 05/11 15:56
Recap: Fusion Pharmaceuticals Q1 Earnings
Benzinga · 05/11 12:50
BRIEF-Fusion Pharmaceuticals Announces Q1 2023 Financial Results And Clinical Program Updates
Reuters · 05/11 11:56
Fusion Pharmaceuticals Q1 EPS $(0.46) Misses $(0.32) Estimate, Sales $28.00K Down From $585.00K YoY; Cash Balance Of $221.2M And $20M Private Placement Financing Extends Cash Runway Into Q2 2025
Benzinga · 05/11 11:40
About FUSN
Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform to enable it to connect alpha-particle emitting isotopes to various targeting molecules to selectively deliver the alpha-particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals; its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, and its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging diagnostics. Its lead product candidate, FPI-1434, utilizes its Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), with actinium-225 or 225Ac.
Webull offers kinds of Fusion Pharmaceuticals Inc stock information, including NASDAQ:FUSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FUSN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading FUSN stock methods without spending real money on the virtual paper trading platform.